Ramipril 10mg Capsules

The full name of your medicine is Ramipril 1.25 mg, 2.5 mg, 5 mg or 10 mg Capsules, but within the leaflet it will be referred to as Ramipril Capsules.

Ramipril Capsules contain a medicine called ramipril. This belongs to a group of medicines called angiotensin-converting enzyme (ACE) inhibitors.

Ramipril Capsules work by:

  • Decreasing your body’s production of substances that could raise your blood pressure.
  • Making your blood vessels relax and widen.
  • Making it easier for your heart to pump blood around your body.

Ramipril Capsules can be used:

  • To treat high blood pressure (hypertension).
  • To reduce the risk of you having a heart attack or stroke.
  • To reduce the risk or delay the worsening of kidney problems (whether or not you have diabetes).
  • To treat your heart when it cannot pump enough blood to the rest of your body (heart failure).
  • As treatment following heart attack (myocardial infarction) complicated with heart failure.

Please contact Crescent Pharma should you require any more information.

Category:

Description

Description

Therapeutic indications for Ramipril 10mg Capsules

  • Treatment of hypertension.
  • Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with:
  • manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease)

or

  • diabetes with at least one cardiovascular risk factor (see section 5.1).
  • Treatment of renal disease:
    • Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,
    • Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor (see section 5.1),
    • Manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥ 3 g/day (see section 5.1).
  • Treatment of symptomatic heart failure.
  • Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Please contact Crescent Pharma should you require any more information.